Review article: Commercialization of whole-plant systems for biomanufacturing of protein products: evolution and prospects
Article first published online: 23 AUG 2010
© 2010 The Author. Plant Biotechnology Journal © 2010 Society for Experimental Biology and Blackwell Publishing Ltd
Plant Biotechnology Journal
Volume 8, Issue 8, pages 845–861, October 2010
How to Cite
Davies, H. M. (2010), Review article: Commercialization of whole-plant systems for biomanufacturing of protein products: evolution and prospects. Plant Biotechnology Journal, 8: 845–861. doi: 10.1111/j.1467-7652.2010.00550.x
- Issue published online: 7 SEP 2010
- Article first published online: 23 AUG 2010
- Received 31 March 2010;revised 21 May 2010;accepted 1 June 2010.
- Plant-made pharmaceuticals;
- molecular farming;
Technology for enabling plants to biomanufacture nonnative proteins in commercially significant quantities has been available for just over 20 years. During that time, the agricultural world has witnessed rapid commercialization and widespread adoption of transgenic crops enhanced for agronomic performance (herbicide-tolerance, insect-resistance), while plant-made pharmaceuticals (PMPs) and plant-made industrial products (PMIPs) have been limited to experimental and small-scale commercial production. This difference in the rate of commercial implementation likely reflects the very different business-development challenges associated with ‘product’ technologies compared with ‘enabling’ (‘platform’) technologies. However, considerable progress has been made in advancing and refining plant-based production of proteins, both technologically and in regard to identifying optimal business prospects. This review summarizes these developments, contrasting today’s technologies and prospective applications with those of the industry’s formative years, and suggesting how the PM(I)P industry’s evolution has generated a very positive outlook for the ‘plant-made’ paradigm.